Key result
ADMA increases bovine pulmonary endothelial cell viability ~30% by inhibiting NO and enhancing urea production.
Why the study?
The effects of asymmetric dimethylarginine (ADMA) on arginase activity and cellular proliferation in pulmonary endothelial cells were unclear, particularly its role in nitric oxide synthase inhibition and arginase-mediated pathways.
ADMA acts as a pro-proliferative agent in pulmonary endothelial cells by inhibiting NO production and enhancing urea production without inhibiting arginase, suggesting a pathophysiological role in pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Does not alter clinical practice; leaves open ADMA's role in endothelial viability for in vivo validation.
Asymmetric dimethylarginine (ADMA) is an endogenously produced nitric oxide synthase (NOS) inhibitor. L-Arginine can be metabolised by NOS and arginase, and arginase is the first step in polyamine production necessary for cellular proliferation. We tested the hypothesis that ADMA would inhibit NOS but not arginase activity and that this pattern of inhibition would result in greater L-arginine bioavailability to arginase, thereby increasing viable cell number. Bovine arginase was used in in vitro activity assays with various concentrations of substrate (L-arginine, ADMA, N(G) -monomethyl-L-arginine (L-NMMA) and N(G) -nitro-L-arginine methyl ester (L-NAME)). Only L-arginine resulted in measurable urea production (Km = 6.9 ± 0.8 mmol/L; Vmax = 6.6 ± 0.3 μmol/mg protein per min). We then incubated bovine arginase with increasing concentrations of ADMA, L-NMMA and L-NAME in the presence of 1 mmol/L l-arginine and found no effect of any of the tested compounds on arginase activity. Using bovine pulmonary arterial endothelial cells (bPAEC) we determined the effects of ADMA on nitric oxide (NO) and urea production and found significantly lower NO production and greater urea production (P < 0.003) with ADMA, without changes in arginase protein levels. In addition, ADMA treatment resulted in an approximately 30% greater number of viable cells after 48 h than in control bPAEC. These results demonstrate that ADMA is neither a substrate nor an inhibitor of arginase activity and that in bPAEC ADMA inhibits NO production and enhances urea production, leading to more viable cells. These results may have pathophysiological implications in disorders associated with higher ADMA levels, such as pulmonary hypertension.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2014) studied this question. Asymmetric dimethylarginine (ADMA) vs. Control was evaluated on Nitric oxide (NO) and urea production, and cell viability (p=< 0.003). In bovine pulmonary arterial endothelial cells, ADMA inhibited NO production and enhanced urea production, resulting in an approximately 30% greater number of viable cells after 48 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: